You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for New Drug Application (NDA): 021520

✉ Email this page to a colleague

« Back to Dashboard

NDA 021520 describes SYMBYAX, which is a drug marketed by Lilly and is included in one NDA. It is available from one supplier. Additional details are available on the SYMBYAX profile page.

The generic ingredient in SYMBYAX is fluoxetine hydrochloride; olanzapine. There are twenty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride; olanzapine profile page.

Summary for 021520

Tradename:	SYMBYAX
Applicant:	Lilly
Ingredient:	fluoxetine hydrochloride; olanzapine
Patents:	0

Pharmacology for NDA: 021520

Mechanism of Action	Serotonin Uptake Inhibitors

Suppliers and Packaging for NDA: 021520

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520	NDA	Eli Lilly and Company	0002-3230	0002-3230-30	30 CAPSULE in 1 BOTTLE (0002-3230-30)
SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520	NDA	Eli Lilly and Company	0002-3231	0002-3231-30	30 CAPSULE in 1 BOTTLE (0002-3231-30)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 25MG BASE;EQ 3MG BASE
Approval Date:	Apr 9, 2007	TE:	AB	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 25MG BASE;EQ 6MG BASE
Approval Date:	Dec 24, 2003	TE:	AB	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 50MG BASE;EQ 6MG BASE
Approval Date:	Dec 24, 2003	TE:	AB	RLD:	Yes

Expired US Patents for NDA 021520

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-003	Dec 24, 2003	5,229,382*PED	⤷ Subscribe
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-005	Dec 24, 2003	5,945,416	⤷ Subscribe
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-002	Dec 24, 2003	5,945,416	⤷ Subscribe
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-004	Dec 24, 2003	6,960,577	⤷ Subscribe
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-001	Apr 9, 2007	5,229,382*PED	⤷ Subscribe
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-005	Dec 24, 2003	6,960,577	⤷ Subscribe
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-004	Dec 24, 2003	5,229,382*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.